Legend Biotech Corporation (LEGN)
NASDAQ: LEGN · Real-Time Price · USD
28.95
-0.02 (-0.07%)
At close: May 30, 2025, 4:00 PM
28.95
0.00 (0.00%)
After-hours: May 30, 2025, 7:22 PM EDT
Legend Biotech Stock Forecast
Stock Price Forecast
According to 11 professional analysts, the 12-month price target for Legend Biotech stock ranges from a low of $55 to a high of $90. The average analyst price target of $77.09 forecasts a 166.29% increase in the stock price over the next year.
Price Target: $77.09 (+166.29%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Legend Biotech stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 6 | 6 | 5 | 4 |
| Buy | 7 | 7 | 7 | 6 | 7 | 7 |
| Hold | 0 | 0 | 0 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 13 | 13 | 13 | 13 | 13 | 12 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Truist Securities | Truist Securities | Strong Buy Maintains $88 → $71 | Strong Buy | Maintains | $88 → $71 | +145.25% | May 14, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $55 | Buy | Reiterates | $55 | +89.98% | May 14, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $84 | Buy | Reiterates | $84 | +190.16% | Apr 22, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +159.07% | Apr 16, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $75 | Strong Buy | Reiterates | $75 | +159.07% | Apr 8, 2025 |
Financial Forecast
Revenue This Year
1.03B
from 627.24M
Increased by 64.21%
Revenue Next Year
1.58B
from 1.03B
Increased by 53.69%
EPS This Year
-0.64
from -0.97
EPS Next Year
0.50
from -0.64
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2B | 1.9B | 2.9B | ||
| Avg | 1.0B | 1.6B | 2.2B | ||
| Low | 906.6M | 1.2B | 1.7B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 87.0% | 88.3% | 82.7% | ||
| Avg | 64.2% | 53.7% | 36.8% | ||
| Low | 44.5% | 16.4% | 10.3% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.28 | 1.40 | 1.80 | ||
| Avg | -0.64 | 0.50 | 1.00 | ||
| Low | -1.32 | -0.21 | 0.45 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 256.8% | ||
| Avg | - | - | 97.9% | ||
| Low | - | - | -10.4% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.